{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:57:07Z","timestamp":1783612627886,"version":"3.55.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","bmn.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Neurobiology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.conb.2024.102898","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T11:19:47Z","timestamp":1722597587000},"page":"102898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Novel therapeutics in development for the treatment of stimulant-use disorder"],"prefix":"10.1016","volume":"87","author":[{"given":"Erica J.","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Radnai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Prikhodko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.conb.2024.102898_sref1","series-title":"World drug report 2023","year":"2023"},{"key":"10.1016\/j.conb.2024.102898_bib2","series-title":"Drugs (psychoactive): impact","author":"Organization","year":"2024"},{"key":"10.1016\/j.conb.2024.102898_bib3","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.4088\/JCP.13r08851","article-title":"A\u00a0review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder","volume":"75","author":"Corp","year":"2014","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.conb.2024.102898_bib4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatr"},{"key":"10.1016\/j.conb.2024.102898_bib5","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jaac.2013.09.005","article-title":"Medical and nonmedical use of prescription stimulants: results from a national multicohort study","volume":"52","author":"McCabe","year":"2013","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.conb.2024.102898_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/pharmacy8010001","article-title":"A\u00a0quantitative and narrative evaluation of goodman and gilman's pharmacological basis of therapeutics","volume":"8","author":"Piper","year":"2019","journal-title":"Pharmacy"},{"key":"10.1016\/j.conb.2024.102898_bib7","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1176\/appi.ajp.2018.17091048","article-title":"Prevalence and correlates of prescription stimulant use, misuse, use disorders, and motivations for misuse among adults in the United States","volume":"175","author":"Compton","year":"2018","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.conb.2024.102898_bib8","series-title":"Results from the 2022 national survey on drug use and health: graphics from the key findings report","year":"2022"},{"key":"10.1016\/j.conb.2024.102898_bib9","series-title":"Results from the 2021 national survey on drug use and health: graphics from the key findings report","year":"2021"},{"key":"10.1016\/j.conb.2024.102898_bib10","series-title":"State unintentional drug overdose reporting system (SUDORS). Final data","year":"2024"},{"key":"10.1016\/j.conb.2024.102898_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109553","article-title":"National polydrug use patterns among people who misuse prescription opioids and people who use heroin. Results from the National Household Survey on Drug Use and Health","volume":"238","author":"Bobashev","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.conb.2024.102898_bib12","series-title":"The New York Times","article-title":"A\u00a0monster\u2019: super meth and other drugs push crisis beyond opioids","author":"Hoffman","year":"2023"},{"key":"10.1016\/j.conb.2024.102898_sref13","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107078","article-title":"IUPHAR Review: new strategies for medications to treat substance use disorders","volume":"200","author":"Montoya","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.conb.2024.102898_bib14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.15585\/mmwr.mm7213a1","article-title":"Trends in stimulant prescription fills among commercially insured children and adults - United States, 2016-2021","volume":"72","author":"Danielson","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.conb.2024.102898_bib15","series-title":"Development & approval process: drugs","article-title":"Patient-focused drug development glossary","year":"2018"},{"key":"10.1016\/j.conb.2024.102898_bib16","series-title":"Patient-focused drug development initiative","article-title":"The voice of the patient: stimulant use disorder","year":"2022"},{"key":"10.1016\/j.conb.2024.102898_bib17","series-title":"Draft guidance","article-title":"Stimulant use disorders: developing drugs for treatment. Guidance for industry","year":"2023"},{"key":"10.1016\/j.conb.2024.102898_bib18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1037\/ccp0000552","article-title":"Long-term efficacy of contingency management treatment based on objective indicators of abstinence from illicit substance use up to 1 year following treatment: a meta-analysis","volume":"89","author":"Ginley","year":"2021","journal-title":"J\u00a0Consult Clin Psychol"},{"key":"10.1016\/j.conb.2024.102898_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234809","article-title":"Treatment of stimulant use disorder: a systematic review of reviews","volume":"15","author":"Ronsley","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.conb.2024.102898_bib20","series-title":"National mental health and substance use policy laboratory: rockville, MD","year":"2020"},{"key":"10.1016\/j.conb.2024.102898_bib21","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/07067437221125301","article-title":"The rising tide of stimulant-related morbidity and mortality warrants evidence-based treatment","volume":"68","author":"Bahji","year":"2023","journal-title":"Can J Psychiatr"},{"key":"10.1016\/j.conb.2024.102898_bib22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/07067437221083505","article-title":"Continuing increase in stimulant dependence - time to implement medical treatment","volume":"67","author":"Bisaga","year":"2022","journal-title":"Can J Psychiatr"},{"key":"10.1016\/j.conb.2024.102898_bib23","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1177\/07067437221148831","article-title":"Evidence-based treatment for stimulant use disorder: time to hit the community","volume":"68","author":"Tardelli","year":"2023","journal-title":"Can J Psychiatr"},{"key":"10.1016\/j.conb.2024.102898_bib24","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2174\/1871527314666150529132723","article-title":"Dopamine D\u2084 receptor antagonists for the treatment of cocaine use disorders","volume":"14","author":"Bergman","year":"2015","journal-title":"CNS Neurol Disord: Drug Targets"},{"key":"10.1016\/j.conb.2024.102898_bib25","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1021\/acs.jmedchem.7b00151","article-title":"Return of D(4) dopamine receptor antagonists in drug discovery","volume":"60","author":"Lindsley","year":"2017","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.conb.2024.102898_bib26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00702-018-1957-2","article-title":"Dopamine and addiction: what have we learned from 40 years of research","volume":"126","author":"Solinas","year":"2019","journal-title":"J\u00a0Neural Transm"},{"key":"10.1016\/j.conb.2024.102898_bib27","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2174\/1871527314666150612150555","article-title":"Synopsis of expert opinions and conclusions","volume":"14","author":"Skolnick","year":"2015","journal-title":"CNS Neurol Disord: Drug Targets"},{"key":"10.1016\/j.conb.2024.102898_bib28","doi-asserted-by":"crossref","first-page":"11250","DOI":"10.1074\/jbc.M116.774075","article-title":"The sigma-1 receptor modulates dopamine transporter conformation and cocaine binding and may thereby potentiate cocaine self-administration in rats","volume":"292","author":"Hong","year":"2017","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.conb.2024.102898_sref29","doi-asserted-by":"crossref","DOI":"10.1016\/j.addicn.2023.100126","article-title":"Recent advances in drug discovery efforts targeting the sigma 1 receptor system: implications for novel medications designed to reduce excessive drug and food seeking","volume":"8","author":"Knowles","year":"2023","journal-title":"Addict Neurosci"},{"key":"10.1016\/j.conb.2024.102898_bib30","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0893-133X(01)00391-8","article-title":"Involvement of the sigma(1) receptor in cocaine-induced conditioned place preference: possible dependence on dopamine uptake blockade","volume":"26","author":"Romieu","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.conb.2024.102898_bib31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.pharmthera.2018.01.009","article-title":"The sigma-1 receptor as a regulator of dopamine neurotransmission: a potential therapeutic target for methamphetamine addiction","volume":"186","author":"Sambo","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.conb.2024.102898_bib32","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/s41467-017-02087-x","article-title":"The sigma-1 receptor modulates methamphetamine dysregulation of dopamine neurotransmission","volume":"8","author":"Sambo","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.conb.2024.102898_bib33","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/cbdd.13841","article-title":"Association of sigma-1 receptor with dopamine transporter attenuates the binding of methamphetamine via distinct helix-helix interactions","volume":"97","author":"Xu","year":"2021","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.conb.2024.102898_bib34","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa2020214","article-title":"Bupropion and naltrexone in methamphetamine use disorder","volume":"384","author":"Trivedi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.conb.2024.102898_bib35","series-title":"Combination treatment for methamphetamine use disorder shows promise in NIH study","year":"2021"},{"key":"10.1016\/j.conb.2024.102898_bib36","series-title":"Probe reports from the NIH molecular libraries program","article-title":"Optimization and characterization of an opioid kappa receptor (OPRK1) antagonist","author":"Guerrero","year":"2010"},{"key":"10.1016\/j.conb.2024.102898_bib37","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41386-019-0398-4","article-title":"Kappa-opioid receptors, dynorphin, and cocaine addiction: a positron emission tomography study","volume":"44","author":"Martinez","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.conb.2024.102898_sref38","doi-asserted-by":"crossref","DOI":"10.1016\/j.addicn.2022.100005","volume":"1","author":"Abraham","year":"2022","journal-title":"Addict Neurosci"},{"key":"10.1016\/j.conb.2024.102898_bib39","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1749-6632.2000.tb06678.x","article-title":"Interactions between kappa opioid agonists and cocaine. Preclinical studies","volume":"909","author":"Mello","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.conb.2024.102898_bib40","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/B978-0-12-420118-7.00012-3","article-title":"Salvinorin A analogs and other \u03ba-opioid receptor compounds as treatments for cocaine abuse","volume":"69","author":"Kivell","year":"2014","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.conb.2024.102898_bib41","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12844","article-title":"Potent and selective NOP receptor activation reduces cocaine self-administration in rats by lowering hedonic set point","volume":"25","author":"Cippitelli","year":"2020","journal-title":"Addiction Biol"},{"key":"10.1016\/j.conb.2024.102898_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109045","article-title":"PPL-138 (BU10038): a bifunctional NOP\/mu partial agonist that reduces cocaine self-administration in rats","volume":"211","author":"Cippitelli","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.conb.2024.102898_sref43","article-title":"Buprenorphine reduces methamphetamine intake and drug seeking behavior via activating nociceptin\/orphanin FQ peptide receptor in rats","volume":"13","author":"Wang","year":"2022","journal-title":"Front Psychiatr"},{"key":"10.1016\/j.conb.2024.102898_bib44","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1176\/appi.ajp.2019.18081007","article-title":"Nociceptin receptors upregulated in cocaine use disorder: a positron emission tomography imaging study using [(11)C]NOP-1A","volume":"176","author":"Narendran","year":"2019","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.conb.2024.102898_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173324","article-title":"The impact of GABA(B) receptors and their pharmacological stimulation on cocaine reinforcement and drug-seeking behaviors in a rat model of depression","volume":"883","author":"Gawli\u0144ska","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.conb.2024.102898_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2024.1347228","article-title":"Restoring GABA(B) receptor expression in the ventral tegmental area of methamphetamine addicted mice inhibits locomotor sensitization and drug seeking behavior","volume":"17","author":"Hleihil","year":"2024","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.conb.2024.102898_bib47","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.pbb.2008.07.005","article-title":"Effects of the combination of metyrapone and oxazepam on cocaine and food self-administration in rats","volume":"91","author":"Goeders","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.conb.2024.102898_bib48","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1177\/0269881111430745","article-title":"Effects of the combination of metyrapone and oxazepam on cocaine craving and cocaine taking: a double-blind, randomized, placebo-controlled pilot study","volume":"26","author":"Kablinger","year":"2012","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.conb.2024.102898_sref49","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1123424","article-title":"Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder","volume":"14","author":"Brett","year":"2023","journal-title":"Front Psychiatr"},{"key":"10.1016\/j.conb.2024.102898_bib50","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1021\/acsmedchemlett.0c00048","article-title":"Psilocybin therapeutic research: the present and future paradigm","volume":"11","author":"Kargbo","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.conb.2024.102898_bib51","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/cns.14054","article-title":"Psilocin suppresses methamphetamine-induced hyperlocomotion and acquisition of conditioned place preference via D2R-mediated ERK signaling","volume":"29","author":"Wang","year":"2023","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.conb.2024.102898_bib52","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/FBP.0b013e328345f90d","article-title":"Serotonin (5-hydroxytryptamine) 5-HT(2A) receptor: association with inherent and cocaine-evoked behavioral disinhibition in rats","volume":"22","author":"Anastasio","year":"2011","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.conb.2024.102898_bib53","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1021\/cn300072u","article-title":"Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction","volume":"4","author":"Cunningham","year":"2013","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.conb.2024.102898_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108009","article-title":"Suppression of cocaine relapse-like behaviors upon pimavanserin and lorcaserin co-administration","volume":"168","author":"Anastasio","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.conb.2024.102898_sref55","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/jnc.15615","article-title":"Beyond monoamines: I. Novel targets and radiotracers for Positron emission tomography imaging in psychiatric disorders","volume":"164","author":"Lopresti","year":"2023","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.conb.2024.102898_bib56","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neuron.2019.01.016","article-title":"The molecular basis of drug addiction: linking epigenetic to synaptic and circuit mechanisms","volume":"102","author":"Nestler","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.conb.2024.102898_bib57","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1471-4159.2009.06004.x","article-title":"Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to D-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons","volume":"109","author":"Sotty","year":"2009","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.conb.2024.102898_bib58","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.MS19053BR3C","article-title":"Current treatment options and emerging agents for schizophrenia","volume":"81","author":"Correll","year":"2020","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.conb.2024.102898_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cells11213385","article-title":"The biological relevance of papaverine in cancer cells","volume":"11","author":"Gomes","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.conb.2024.102898_bib60","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/PL00007090","article-title":"Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction","volume":"19","author":"Uckert","year":"2001","journal-title":"World J Urol"},{"key":"10.1016\/j.conb.2024.102898_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.1003617","article-title":"Low and high dose methamphetamine differentially regulate synaptic structural plasticity in cortex and hippocampus","volume":"16","author":"Ding","year":"2022","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.conb.2024.102898_bib62","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.conb.2018.08.013","article-title":"Synaptic and intrinsic plasticity in the ventral tegmental area after chronic cocaine","volume":"54","author":"Francis","year":"2019","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.conb.2024.102898_bib63","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/npp.2017.90","article-title":"Reversal of cocaine-associated synaptic plasticity in medial prefrontal cortex parallels elimination of memory retrieval","volume":"42","author":"Otis","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.conb.2024.102898_bib64","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1523\/JNEUROSCI.2182-19.2020","article-title":"Methamphetamine learning induces persistent and selective nonmuscle myosin II-dependent spine motility in the basolateral amygdala","volume":"40","author":"Young","year":"2020","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.conb.2024.102898_bib65","doi-asserted-by":"crossref","first-page":"10867","DOI":"10.1523\/JNEUROSCI.1821-17.2017","article-title":"Circuit and synaptic plasticity mechanisms of drug relapse","volume":"37","author":"Dong","year":"2017","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.conb.2024.102898_bib66","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.biopsych.2016.04.003","article-title":"AMPA receptor plasticity in accumbens core contributes to incubation of methamphetamine craving","volume":"80","author":"Scheyer","year":"2016","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.conb.2024.102898_bib67","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/164_2016_29","article-title":"Myosins: domain organisation, motor properties, physiological roles and cellular functions","volume":"235","author":"Masters","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.conb.2024.102898_bib68","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1523\/JNEUROSCI.3294-10.2011","article-title":"Regulation of synapse structure and function by distinct myosin II motors","volume":"31","author":"Rubio","year":"2011","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.conb.2024.102898_bib69","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mcn.2014.05.008","article-title":"Myosin IIb controls actin dynamics underlying the dendritic spine maturation","volume":"61","author":"Koskinen","year":"2014","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.conb.2024.102898_bib70","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/mp.2015.103","article-title":"Nonmuscle myosin IIB as a therapeutic target for the prevention of relapse to methamphetamine use","volume":"21","author":"Young","year":"2016","journal-title":"Mol Psychiatr"},{"key":"10.1016\/j.conb.2024.102898_bib71","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.nlm.2017.01.001","article-title":"Nonmuscle myosin II inhibition disrupts methamphetamine-associated memory in females and adolescents","volume":"139","author":"Young","year":"2017","journal-title":"Neurobiol Learn Mem"},{"key":"10.1016\/j.conb.2024.102898_bib72","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0162-3109(92)90023-6","article-title":"A\u00a0potential vaccine for cocaine abuse prophylaxis","volume":"23","author":"Bagasra","year":"1992","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.conb.2024.102898_bib73","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1021\/acs.jmedchem.3c00366","article-title":"Anti-cocaine vaccine development: where are we now and where are we going?","volume":"66","author":"Stephenson","year":"2023","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.conb.2024.102898_sref74","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110210","article-title":"Future perspectives of emerging novel drug targets and immunotherapies to control drug addiction","volume":"119","author":"Malik","year":"2023","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.conb.2024.102898_bib75","doi-asserted-by":"crossref","first-page":"892","DOI":"10.2174\/187152711799219370","article-title":"Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction","volume":"10","author":"Owens","year":"2011","journal-title":"CNS Neurol Disord: Drug Targets"},{"key":"10.1016\/j.conb.2024.102898_bib76","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4161\/mabs.27620","article-title":"Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use","volume":"6","author":"Stevens","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.conb.2024.102898_bib77","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1080\/21645515.2017.1294955","article-title":"InterveXion therapeutics","volume":"13","author":"Stevens","year":"2017","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.conb.2024.102898_bib78","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.4161\/19420862.2014.976431","article-title":"First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers","volume":"6","author":"Stevens","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.conb.2024.102898_bib79","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.intimp.2016.03.028","article-title":"Optimization of a methamphetamine conjugate vaccine for antibody production in mice","volume":"35","author":"Stevens","year":"2016","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.conb.2024.102898_bib80","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1016\/j.vaccine.2013.07.038","article-title":"Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food","volume":"31","author":"R\u00fcedi-Bettschen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.conb.2024.102898_bib81","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00213-019-05399-6","article-title":"Effects of a methamphetamine vaccine, IXT-v100, on methamphetamine-related behaviors","volume":"237","author":"Keller","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.conb.2024.102898_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.05.016","article-title":"Antibody production and pharmacokinetics of METH in rats following vaccination with the METH vaccine, IXT-v100, adjuvanted with GLA-SE","volume":"204","author":"Stevens","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.conb.2024.102898_bib83","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1176\/appi.prcp.20180006","article-title":"Pharmacological and behavioral treatment of opioid use disorder","volume":"1","author":"Sofuoglu","year":"2019","journal-title":"Psychiatr Res Clin Pract"},{"key":"10.1016\/j.conb.2024.102898_bib84","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8279","article-title":"Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: a systematic review and meta-analysis","volume":"3","author":"Ray","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.conb.2024.102898_bib85","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1586\/17512433.2014.909283","article-title":"Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research","volume":"7","author":"Stoops","year":"2014","journal-title":"Expet Rev Clin Pharmacol"},{"key":"10.1016\/j.conb.2024.102898_bib86","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s40614-019-00214-1","article-title":"Technology-based contingency management in the treatment of substance-use disorders","volume":"42","author":"Dallery","year":"2019","journal-title":"Perspect Behav Sci"},{"key":"10.1016\/j.conb.2024.102898_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.778992","article-title":"A\u00a0smartphone-smartcard platform for implementing contingency management in buprenorphine maintenance patients with concurrent stimulant use disorder","volume":"12","author":"DeFulio","year":"2021","journal-title":"Front Psychiatr"},{"key":"10.1016\/j.conb.2024.102898_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2021.106881","article-title":"Methamphetamine use and technology-mediated psychosocial interventions: a mini-review","volume":"121","author":"Rubenis","year":"2021","journal-title":"Addict Behav"}],"container-title":["Current Opinion in Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959438824000606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959438824000606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T21:08:07Z","timestamp":1737320887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959438824000606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":88,"alternative-id":["S0959438824000606"],"URL":"https:\/\/doi.org\/10.1016\/j.conb.2024.102898","relation":{},"ISSN":["0959-4388"],"issn-type":[{"value":"0959-4388","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapeutics in development for the treatment of stimulant-use disorder","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Neurobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conb.2024.102898","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102898"}}